Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Participants in the trial had an average age of 44.7 years, a mean body weight of 113 kg (249 lbs), and a body mass index (BMI) of 39.4 kg/m². Most had been living with obesity for about 16 years ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

The tirzepatide group had more injection-site reactions than the semaglutide group, which is consistent with other SURMOUNT trials. 14,20 In the current trial, no participants were reported to ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

The mean decrease in waist circumference for those on tirzepatide was 18.4 cm/7.2 in, and for those on semaglutide it was 13 cm/5.1 in – 42% higher for tirzepatide.

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. First head-to-head trial compares tirzepatide and semaglutide - Results are in ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...